InflaRx Assessing Feasibility of Broadened Strategy for ANCA?Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

Stock Information for InflaRx N.V.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InflaRx N.V.

InflaRx Announces Participation in September Investor Conferences
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
InflaRx to Report First Quarter 2026 Results on May 7, 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.